Opening Broadway again could work wonders for local hotels and also drive more people back to the city.
Vancouver, British Columbia--(Newsfile Corp. - May 11, 2021) - Eastern Platinum Limited (TSX: ELR) (JSE: EPS) ("Eastplats" or the "Company") is pleased to report the Company has dispatched 199.8 dry tons of platinum group metal ("PGM") concentrates containing 490.9 oz of PGMs under the offtake agreement with Impala Platinum Limited, within the production month of April 2021. This marks the first full month of PGM production following the recent completion of the reconfiguration ...
The last four ATP Masters 1000 events -- the most prestigious tournaments outside the Grand Slams -- have been won by players outside the 'Big Three' of Djokovic, Rafa Nadal and Roger Federer. Russian Daniil Medvedev, 25, won the ATP Finals and the Paris Masters titles last year and has already displaced Spaniard Nadal from second spot.
Hong Kong officials dropped a plan to mandate foreign domestic workers be vaccinated against the coronavirus, after hearing international criticism the move would be discriminatory. Most of Hong Kong’s approximately 370,000 domestic workers come from Indonesia and the Philippines, both severely impacted by the pandemic. Hong Kong officials initially proposed the mandate after a foreign domestic worker tested positive for a coronavirus variant in April, with an unknown source of infection. Another worker arriving from the Philippines had also tested positive for a variant. Those findings prompted the city to order domestic workers to be tested for the virus at the end of April. The plan for mandatory vaccinations was dropped after officials assessed public health needs and the potential legal issues, Hong Kong leader Carrie Lam said at a regular news briefing Tuesday. The Philippines’ Secretary of Foreign Affairs Teodoro Locsin Jr. previously slammed the Hong Kong government for its mandatory vaccination plan for foreign domestic workers, saying that it “smacks of discrimination.” On Tuesday, Lam also announced a second round of mandatory tests for domestic workers as a precaution, which will begin on Saturday and last until the end of the May. She urged employers to allow the workers to take the test on a workday instead of on their day off. Hong Kong has so far reported 11,812 infections of the coronavirus, with 210 deaths. Indonesia has reported more than 1.7 million people infected and 47,000 deaths, while the Philippines has confirmed 1.1 million infections and 18,500 deaths from COVID-19. The Associated Press
Alongside the journey through Dylan’s artistic landscape, the new exhibition will include curated immersive and interactive displays of his music and literary works adding context of this multi-faceted talent and his impact on popular culture spanning over half a century.
The government will set out its legislative agenda for the new parliamentary session in the Queen's Speech today. It will also be the Queen's first major public ceremonial duty since the death of her husband, the Duke of Edinburgh. Here's what to expect in the speech, which you can watch and follow live from 10.30am on Sky News, online, and on the Sky News app.
On Monday, a huge crowd gathered outside AIADMK headquarters, in clear violation of the lockdown norms.
The Financial Conduct Authority (FCA) said in a letter to Amigo that it was concerned customers' compensation claims would be significantly reduced while shareholders were not being asked to contribute, the company said. Amigo said over 95% of votes cast by current and former customers to date were in favour of the scheme, ahead of a creditors' meeting on Wednesday. Amigo's rescue plan has drawn criticism from politicians and consumer groups for potentially short-changing customers.
‘There is evidence the actor’s ransomware is in Russia,’ US president says
Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) ("Takeda") today announced financial results for fiscal year 2020 (period ended March 31, 2021).
Sirens sounded in Ashkelon, Israel, as the Iron Dome defence system intercepted several missiles fired at the city from Gaza early on May 11.Six people were injured after rockets struck two homes in the city in southern Israel, according to local news reports.The Israel Defence Force (IDF) claimed over 200 rockets were sent into the country and retaliated with launches of its own into Gaza. The IDF said it killed 15 Hamas “terrorists”, while the Palestinian Ministry of Health in Gaza said 20 people including 9 children were killed.“I had to run back home which is two minutes from the house. People were running and panicking,” Nikia Shantrice Browne, who filmed this video, told Storyful. Credit: Nikia Shantrice Browne via Storyful
The Israeli military has insisted it does all it can to avoid civilian deaths after 22 people, including nine children, were killed overnight in the Gaza Strip. Israeli fighter jets, attack helicopters and drones hit more than 130 "Hamas military targets", including the home of a Hamas commander, according to the Israeli military. The airstrikes were a retaliation for a barrage of rockets fired into Israel from Gaza since 6pm on Monday including six rockets which landed near Jerusalem.
‘They’ve not held up their end of the bargain,’ says one who worked in ‘war zone’ hospitals during pandemic
City regulator pledges to oppose plan in court
Kevin Jones, our chief executive officer, and Amar Maletira, our president and chief financial officer, join us today. Rackspace Technology assumes no obligation to update the information presented on the call except as required by law.
May 11, 2021 This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail. Continued focus on Sweden to meet increased demand, SaaS subscriptions on a steady level January – March 2021 • Net sales were KSEK 5,770 (6,085) *• Profit/loss after financial items was KSEK -3,570 (-3,569)• The operating result was KSEK -3,355 (-4,987)• Earnings per share were SEK -0.1 (-0.2) * The decrease in net sales is attributable to changes in exchange rates. At the end of Q1 2021, the company had about MSEK 2.1 in accounts receivable from result-based contracts, accrued during Q42018–Q42020, of which SEK 2 million have been taken up as revenue during Q4 2019 and Q4 2020. During the first quarter of the year, we have seen that the sales situation has stabilised and we can see that our sales pipeline is growing again. We have gained new clients – including DHL Supply Chain Sweden AB, which has initiated a pilot project that is currently being implemented. We are very pleased to be working with one of the largest employers in the world and look forward to a long collaboration after the pilot phase. In Finland, Wihuri Oy has chosen to extend their HealthManager licenses to the operations throughout Finland, which has added another 700 SaaS subscribers. We have continued to invest heavily in marketing and sales, especially in Sweden. This has resulted in higher costs but has also had results in the form of increased activity levels, the outcome of which will be seen in the coming quarters. As of the last of March, we have around 50,000 subscribers. Thanks to the improved sales situation in Sweden and the high activity level we have, I look forward to a continued strong 2021 that will bring us new clients, better visibility for Aino and an even better SaaS solution that will continue to support our clients in keeping their employees healthy and engaged. Jyrki EklundCEO and President Aino Health AB The information contained herein is such as shall be made public by Aino Health AB (publ), in accordance with the EU Market Abuse Regulation. This information was made public, through the agency of Jyrki Eklund, CEO and President of Aino Health AB, at 08.30 AM CET on May 11, 2021. For more information:Jyrki Eklund, CEO Aino Health, Phone: +358 40 042 4221 Certified adviserErik Penser Bank+46 8 463 83 email@example.com About Aino Health (publ) Aino Health is the leading supplier of Software as a Service solutions in Corporate Health Management. The company’s complete system of SaaS platforms and services reduces sick leave, lowers related costs, and improves business results through increased productivity and employee engagement by making health, wellbeing, and safety an integrated part of everyday work. For more information visit ainohealth.com. Aino Health AB (publ) is listed on Nasdaq First North Growth Market (Ticker: AINO). For more information: https://investors.ainohealth.com/en. Attachments Aino_Q1_2021-ENG PR Aino Q1-2021 ENG
In a Phase 3 trial, the vaccine was 100% effective and generally well tolerated in participants aged 12 to 15 years Data also submitted to European Medicines Agency (EMA) and other global regulators, with additional authorizations expected in coming weeks NEW YORK and MAINZ, GERMANY, May 11, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for their COVID-19 vaccine to include individuals 12 to 15 years of age. This is the first COVID-19 vaccine authorized in the U.S. for use in this age group. “Today’s expansion of our EUA represents a significant step forward in helping the U.S. government broaden its vaccination program and help protect adolescents before the start of the next school year,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “We are grateful to all of our clinical trial volunteers and their families, whose courage helped make this milestone possible. Together, we hope to help bring a sense of normalcy back to young people across the country and around the world.” The FDA based its decision on data from a pivotal Phase 3 clinical trial, which enrolled 2,260 participants aged 12 to 15 years. Topline results from this trial, announced on March 31, 2021, showed a vaccine efficacy of 100% in participants with or without prior SARS-CoV-2 infection and robust antibody responses. In the trial, the vaccine was also generally well tolerated. Participants will continue to be monitored for long-term protection and safety for an additional two years after their second dose. As a next step following today’s FDA decision, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) will meet to discuss recommendations for use of the Pfizer-BioNTech COVID-19 Vaccine in adolescents 12 to 15 years of age based on the amended EUA. “Since securing the EUA in December for individuals 16 years and older, we have been working tirelessly to get our COVID-19 vaccine authorized around the world so that governments can provide it to as many people as possible,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “Our work is not yet complete, as we continue our research into the use of our vaccine in pediatric populations. Our goal is to submit data for pre-school and school-age children in September.” Pfizer and BioNTech have submitted the data in adolescents 12 to 15 years of age for scientific peer review for potential publication. The data also have been submitted to other regulators around the world, including the European Medicines Agency (EMA). In addition, the pediatric study evaluating the safety and efficacy of the Pfizer-BioNTech COVID-19 vaccine in children 6 months to 11 years of age is ongoing. Pfizer and BioNTech expect to have definitive readouts, and subject to the data generated, submit for an EUA or a variation to Conditional Marketing Authorizations for two cohorts, including children 2-5 years of age and 5-11 years of age, in September. The readout and submission for the cohort of children 6 months to 2 years of age are expected in the fourth quarter. The Pfizer-BioNTech COVID-19 vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the European Union, and the holder of emergency use authorizations or equivalents in the United States (together with Pfizer), United Kingdom, Canada and other countries in advance of a planned application for full marketing authorizations in these countries. The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for use in individuals 12 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564 (b) (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full EUA Prescribing Information available at www.cvdvaccine-us.com. AUTHORIZED USE IN THE U.S.: The Pfizer-BioNTech COVID19 vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older. IMPORTANT SAFETY INFORMATION FROM U.S. FDA EMERGENCY USE AUTHORIZATION PRESCRIBING INFORMATION: Do not administer Pfizer-BioNTech COVID-19 vaccine to individuals with known history of a severe allergic reaction (eg, anaphylaxis) to any component of the Pfizer-BioNTech COVID-19 vaccine Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer-BioNTech COVID-19 vaccineMonitor Pfizer-BioNTech COVID-19 vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html)Syncope (fainting) may occur in association with administration of injectable vaccines, in particular in adolescents. Procedures should be in place to avoid injury from faintingImmunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 vaccine The Pfizer-BioNTech COVID-19 vaccine may not protect all vaccine recipients In clinical studies, adverse reactions in participants 16 years of age and older included pain at the injection site (84.1%), fatigue (62.9%), headache (55.1%), muscle pain (38.3%), chills (31.9%), joint pain (23.6%), fever (14.2%), injection site swelling (10.5%), injection site redness (9.5%), nausea (1.1%), malaise (0.5%), and lymphadenopathy (0.3%) In a clinical study, adverse reactions in adolescents 12 through 15 years of age included pain at the injection site (90.5%), fatigue (77.5%), headache (75.5%), chills (49.2%), muscle pain (42.2%), fever (24.3%), joint pain (20.2%), injection site swelling (9.2%), injection site redness (8.6%), lymphadenopathy (0.8%), and nausea (0.4%)Severe allergic reactions, including anaphylaxis, and other hypersensitivity reactions, diarrhea, vomiting, and pain in extremity (arm) have been reported following administration of the Pfizer-BioNTech COVID-19 vaccine outside of clinical trials. Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Pfizer-BioNTech COVID-19 vaccineAvailable data on Pfizer-BioNTech COVID-19 vaccine administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy Data are not available to assess the effects of Pfizer-BioNTech COVID-19 vaccine on the breastfed infant or on milk production/excretion There are no data available on the interchangeability of the Pfizer-BioNTech COVID-19 vaccine with other COVID-19 vaccines to complete the vaccination series. Individuals who have received one dose of Pfizer-BioNTech COVID-19 vaccine should receive a second dose of Pfizer-BioNTech COVID-19 vaccine to complete the vaccination series Vaccination providers must report Adverse Events in accordance with the Fact Sheet to VAERS online at https://vaers.hhs.gov/reportevent.html. For further assistance with reporting to VAERS call 1-800-822-7967. The reports should include the words “Pfizer-BioNTech COVID-19 Vaccine EUA” in the description section of the report Vaccination providers should review the Fact Sheet for Information to Provide to Vaccine Recipients/Caregivers and Mandatory Requirements for Pfizer-BioNTech COVID-19 vaccine Administration Under Emergency Use Authorization Before administration of Pfizer-BioNTech COVID-19 vaccine, please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including Full EUA Prescribing Information available at www.cvdvaccine-us.com. About Pfizer: Breakthroughs That Change Patients’ LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer. Pfizer Disclosure Notice The information contained in this release is as of May 11, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) (including qualitative assessments of available data, potential benefits, expectations for clinical trials, the potential of BNT162b2 for adolescents 12 to 15 years of age, evaluation of BNT162b2 in children 6 months to 11 years old, anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the topline data outlined in this release), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data (including the topline data outlined in this release); the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data (including the topline data outlined in this release) are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program (including the topline data outlined in this release) will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when a Biologics License Application for BNT162b2 may be filed in the U.S. and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including a potential Biologics License Application in the U.S. or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. About BioNTech Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de. BioNTech Forward-looking Statements This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine (including a potential second booster dose of BNT162b2 and/or a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence); the potential of BNT162b2 for adolescents 12 to 15 years of age, evaluation of BNT162b2 in children 6 months to 11 years old, anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; the risk that demand for any products may be reduced or no longer exist; the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021; and challenges related to public vaccine confidence or awareness. Any forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties. For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report on Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law. Pfizer Contacts: Media RelationsAmy Rose+1 (212) 733-7410 Amy.Rose@pfizer.com Investor RelationsChuck Triano+1 (212) 733-3901Charles.E.Triano@Pfizer.com BioNTech Contacts: Media RelationsJasmina Alatovic+49 (0)6131 9084 1513 Media@biontech.de Investor RelationsSylke Maas, Ph.D.+49 (0)6131 9084 1074Investors@biontech.de
Good morning, Please find below the press release issued today. Best regards,___________________________________________________________________ Marishka MartinsGroup PR Consultant | Marketing & Creative Services Capgemini India | Mumbaiwww.capgemini.com Tel.: +91 9930835325 Email: firstname.lastname@example.org_____________________________ Capgemini to enable a “Digital Workplace” transformation at Airbus Paris, France – Mai 11, 2021 - Capgemini has signed a five-year contract with Airbus to support the redesign of its global collaborative workplace, both in terms of working methods and tools. In terms of tools and technology Capgemini will enable online publishing and sharing services, collaboration and productivity tools, messaging services, instant messaging, video conferencing, and digital telephony services. "It was our ability to handle this project end-to-end, from strategic scoping through to operational transformation, integrating new technologies and cloud, that made the difference. We are extremely proud to be supporting Airbus in this major redesign,” said Nive Bhagat, CEO of Capgemini’s Cloud & Infrastructure Services and member of the Group Executive Committee. About CapgeminiCapgemini is a global leader in partnering with companies to transform and manage their business by harnessing the power of technology. The Group is guided everyday by its purpose of unleashing human energy through technology for an inclusive and sustainable future. It is a responsible and diverse organization of 270,000 team members in nearly 50 countries. With its strong 50 year heritage and deep industry expertise, Capgemini is trusted by its clients to address the entire breadth of their business needs, from strategy and design to operations, fueled by the fast evolving and innovative world of cloud, data, AI, connectivity, software, digital engineering and platforms. The Group reported in 2020 global revenues of €16 billion.Get the Future You Want | www.capgemini.com Attachment Capgemini_Airbus_Digital WorkPlace_EN
EMG, a leading global provider of broadcast facilities and media solutions, announced today that Shaun Gregory will join the company as Group CEO.
It remains unclear whether the teenager will be charged as a juvenile or as an adult
Manchester United are juggling a tough Premier League run-in but have guaranteed a top-four finish as they tonight welcome a Leicester City side still nervy about their own Champions League hopes. A win at Aston Villa was the start of a run of three games in five days for Ole Gunnar Solskjaer & Co. culminating with the rescheduled visit of Liverpool on Thursday. Leicester went down 4-2 at home to Newcastle but West Ham’s own defeat to Everton have given them some much-needed breathing space in their bid to finish fourth or higher.